Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

O Decaux

Showing results (41-50 of 46) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 46 results.
Leukemia|July 30, 2011
Cytogenetic and therapeutic characterization of primary plasma cell leukemia: the IFM experienceH Avet-Loiseau, M Roussel, L Campion, et al.
Leukemia|April 5, 2017
Benefit of continuous treatment for responders with newly diagnosed multiple myeloma in the randomized FIRST trialN J Bahlis, A Corso, L-O Mugge, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 27, 2024
Real-Life Management of Patients Aged 80 Years Old and Over With Multiple Myeloma: Results of the EMMY CohortT Chalopin, M Macro, O Decaux, et al.
Lupus|March 31, 2017
Cessation of oral anticoagulants in antiphospholipid syndromeC Comarmond, P Jego, C Veyssier-Belot, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 21, 2016
Safe and prolonged survival with long-term exposure to pomalidomide in relapsed/refractory myelomaG Fouquet, B Pegourie, M Macro, et al.
British Journal of Haematology|May 15, 2024
French early nationwide idecabtagene vicleucel chimeric antigen receptor T-cell therapy experience in patients with relapsed/refractory multiple myeloma (FENIX): A real-world IFM study from the DESCAR-T registryB Ferment, J Lambert, D Caillot, et al.
Pageof 5

Showing results (41-50 of 46) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 46 results.
Leukemia|July 30, 2011
Cytogenetic and therapeutic characterization of primary plasma cell leukemia: the IFM experienceH Avet-Loiseau, M Roussel, L Campion, et al.
Leukemia|April 5, 2017
Benefit of continuous treatment for responders with newly diagnosed multiple myeloma in the randomized FIRST trialN J Bahlis, A Corso, L-O Mugge, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 27, 2024
Real-Life Management of Patients Aged 80 Years Old and Over With Multiple Myeloma: Results of the EMMY CohortT Chalopin, M Macro, O Decaux, et al.
Lupus|March 31, 2017
Cessation of oral anticoagulants in antiphospholipid syndromeC Comarmond, P Jego, C Veyssier-Belot, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 21, 2016
Safe and prolonged survival with long-term exposure to pomalidomide in relapsed/refractory myelomaG Fouquet, B Pegourie, M Macro, et al.
British Journal of Haematology|May 15, 2024
French early nationwide idecabtagene vicleucel chimeric antigen receptor T-cell therapy experience in patients with relapsed/refractory multiple myeloma (FENIX): A real-world IFM study from the DESCAR-T registryB Ferment, J Lambert, D Caillot, et al.
Pageof 5